Last Updated on October 10, 2024 by The Health Master
USFDA inspections
In a significant development, India is gearing up for the 14th Trade Policy Forum (TPF) meeting, a crucial platform to address trade and investment issues between the United States and India by way of faster USFDA Inspections.
Scheduled to be co-chaired by US Trade Representative Katherine Tai and Commerce and Industry Minister Piyush Goyal, the meeting is poised to tackle several pivotal matters that hold immense importance for both nations.
USFDA Inspections: A Critical Demand from India
India will assertively demand the expedited USFDA inspections process by the United States Food and Drug Administration (USFDA) for Indian pharmaceutical manufacturing units.
The article delves into the intricacies of the USFDA approval process, its impact on the pharmaceutical export market, and the challenges faced during the pandemic-induced disruptions.
Reinstating Generalized System of Preferences (GSP) Status
A significant concern to be raised by the Indian delegation is the reinstatement of the Generalized System of Preferences (GSP) status for India.
The section explores the history of GSP benefits, their abrupt termination in 2019, and India’s plea for resumption on various platforms.
Export Control Regulations for High-Tech Products
India’s aspirations to be recognized as a Trade Agreements Act (TAA) designated country by the US will be discussed, emphasizing the importance of export control regulations for high-tech products and technologies.
Challenges in the Shrimp Export Market
The US ban on Indian wild-caught shrimp exports poses a significant challenge for India.
This section examines the reasons behind the ban, India’s response, and the upcoming TED workshop proposed by the US National Oceanic and Atmospheric Administration (NOAA) team.
Reviewing Bilateral Trade Relations
An analysis of the current state of bilateral trade between the two nations, highlighting the key sectors and the role of the TPF in resolving trade and investment issues.
This section provides insights into the growth trajectory of the trade relationship.
India’s Interest in GSP Resumption
Diving deeper into India’s multiple pleas on various platforms to resume incentives under the GSP program.
The article sheds light on the grounds for the initiation of the GSP review by the USTR office in 2018 and the subsequent termination of India’s GSP benefits in 2019.
Impact of USFDA Inspections on Pharma Exports
A closer look at how the pandemic disrupted USFDA inspections in India, causing a backlog that affected product and unit approvals.
This section explores the implications of delayed inspections on the pharmaceutical export market and the proposed solutions.
India’s Efforts for GSP Resumption
Examining India’s continuous efforts to seek the resumption of GSP benefits, analyzing the reasons behind the program’s suspension, and the subsequent increase in exports under GSP tariff lines.
Trade Policy Forum (TPF): A Brief Overview
Providing readers with a comprehensive understanding of the TPF, its structure, and the focus groups involved—agriculture, investment, innovation, creativity (intellectual property rights), services, and tariff and non-tariff barriers.
US as India’s Largest Trading Partner
Highlighting the significance of the US as India’s largest trading partner and its role in both goods and services sectors.
The article explores the growth in bilateral trade and the substantial foreign direct investment from the US in the past fiscal year.
Bridging the Gaps for Mutual Prosperity
Summarizing the key takeaways from the TPF meeting, emphasizing the need for collaborative efforts to address trade and investment challenges.
The conclusion serves as a call to action for both nations to strengthen their diplomatic ties for mutual prosperity.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Challenges Faced by MSME Pharma Industries on Revised Schedule M
Pharma Revolution: UP’s Grand Plan for Lalitpur’s Pharma Park
NPPA is set to fix the ceiling prices for more than 200 formulations
Biopharmaceutical Affordability: Decoding the Complex Equation by Dr Tumbagi
Drug recall: Dr Reddy’s recalls over 8,000 bottles of generic drug due to packaging error
NPPA fixed retail price of 19 formulations: January 2024
DCGI to Blood Centres: Comply with revised guidelines for recovery of processing charges
The Indian Pharmacopoeia Commission: Bidding for Pharmaceutical Impurities
Govt revises Schedule M: Revolutionizing Pharmaceutical Manufacturing
New class of antibiotics developed to fight drug-resistant bacteria
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
